Published: 17 January 2024
Author(s): Mehdi Madanchi, Mabelle Young, Gregorio Tersalvi, Giacomo Maria Cioffi, Adrian Attinger-Toller, Florim Cuculi, Reto Kurmann, Matthias Bossard
Issue: May 2024
Section: Review Article

Inflammation is a major contributor in the development and progression of coronary artery disease (CAD). Preclinical studies have demonstrated that inflammatory processes, by means of specific cytokines and enzymes, promotes plaque formation, progression and instability [1,2]. Furthermore, patients with chronic inflammatory disease (e.g. rheumatoid arthritis, gout) have a high incidence of CAD [3,4]. Hence, by targeting inflammatory pathways, the risk for cardiovascular (CV) events may potentially be diminished [5,6].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.